Pancreatic Cancer Research

ResearcherFirst Affiliated Hospital Zhejiang UniversityActive in the last 2 years

Xiang Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6145-7045; OpenAlex author ID A5077050832. Sources: OpenAlex.

Their work

Papers
6 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
27
Papers, trials and grants by year

2023: 2 papers · 2024: none · 2025: 4 papers

Papers 6

  1. 5-Year survival rate over 20 % in pancreatic ductal adenocarcinoma: A retrospective study from a Chinese high-volume center. Co-author DOI 10.1016/j.canlet.2025.217658↗
  2. Neoadjuvant nab-paclitaxel plus gemcitabine followed by modified FOLFIRINOX for resectable pancreatic cancer: A randomized phase 3 trial. First author DOI 10.1016/j.ccell.2025.09.009↗
  3. Efficacy of Neoadjuvant Therapy and the Prognostic Significance of Serum Carcinoembryonic Antigen Level in Patients with Localized Pancreatic Adenocarcinoma wi… First author DOI 10.1097/sla.0000000000006719↗
  4. Elevated protein lactylation promotes immunosuppressive microenvironment and therapeutic resistance in pancreatic ductal adenocarcinoma. Co-author DOI 10.1172/jci187024↗
  5. Normalization of tumor markers and a clear resection margin affect progression-free survival of patients with unresectable pancreatic cancer who have undergone… Co-author DOI 10.1186/s12885-023-10529-7↗
  6. Sintilimab Plus Modified FOLFIRINOX in Metastatic or Recurrent Pancreatic Cancer: The Randomized Phase II CISPD3 Trial. Co-author DOI 10.1245/s10434-023-13383-w↗

Closest collaborators

The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tingbo Liang · 4 shared papers, 2023–2025 · strength 0.77
  2. Risheng Que · 4 shared papers, 2023–2025 · strength 0.69
  3. Guoliang Qiao · 3 shared papers, 2025 · strength 0.62
  4. Xueli Bai · 3 shared papers, 2025 · strength 0.62
  5. Tingbo Liang · 3 shared papers, 2023–2025 · strength 0.46
  6. Tianan Jiang · 2 shared papers, 2025 · strength 0.39
  7. Qi Zhang · 2 shared papers, 2025 · strength 0.39
  8. Xueli Bai · 2 shared papers, 2023–2025 · strength 0.31
  9. Min Zhang · 2 shared papers, 2023 · strength 0.29
  10. Louisa Bolm · 1 shared paper, 2025 · strength 0.22
  11. Yiwen Chen · 1 shared paper, 2025 · strength 0.22
  12. Zhiyong Yang · 1 shared paper, 2025 · strength 0.22
  13. Motaz Qadan · 1 shared paper, 2025 · strength 0.22
  14. Keith D. Lillemoe · 1 shared paper, 2025 · strength 0.22
  15. Xiao Zhi · 1 shared paper, 2025 · strength 0.17
  16. Hanshen Yang · 1 shared paper, 2025 · strength 0.17
  17. Lihong He · 1 shared paper, 2025 · strength 0.17
  18. Lingyue Liu · 1 shared paper, 2025 · strength 0.17
  19. Mao Ye · 1 shared paper, 2025 · strength 0.17
  20. Xiongbin Lu · 1 shared paper, 2025 · strength 0.17
  21. Kang Sun · 1 shared paper, 2025 · strength 0.17
  22. Jinyuan Song · 1 shared paper, 2025 · strength 0.17
  23. Mengyi Lao · 1 shared paper, 2025 · strength 0.17
  24. Qi Zhang · 1 shared paper, 2023 · strength 0.15
  25. Qihan Fu · 1 shared paper, 2023 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.